TG Therapeutics, Inc. Announces Clinical Data Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Milan, Italy

TG Therapeutics Logo

NEW YORK, May 22, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced upcoming presentations of clinical data for TG-1101, the Company's next generation, glycoengineered anti-CD20 monoclonal antibody and for TGR-1202, the Company's novel, once-daily PI3k delta inhibitor, at the 19th Congress of the European Hematology Association (EHA), being held June 12 – 15, 2014 in Milan, Italy. Copies of the EHA abstracts are available online through the EHA meeting website at

The following abstracts have been accepted for presentation:

  • Title: Ublituximab (TG-1101), a novel glycoengineered anti-CD20 MAB, in combination with ibrutinib in patients with CLL and MCL; results of an ongoing phase II trial
    • Abstract Number: P880
    • Date and Time: Saturday June 14, 2014, 5:45 -7:00pm CEST
    • Poster Display: NW – Level 0
    • Lead Author: Jeff P. Sharman, MD
  • Title: Ublituximab (TG-1101), a novel anti-CD20 monoclonal for rituximab relapsed/refractory B-Cell malignancies
    • Abstract Number: P444
    • Date and Time: Friday June 13, 2014, 5:45pm – 7:00pm CEST
    • Poster Display: NW – Level 0
    • Lead Author: Owen A. O'Connor, MD, PhD
  • Title: TGR-1202, a novel once daily PI3K delta inhibitor, demonstrates promising clinical activity with a favorable safety profile in patients with relapsed or refractory hematologic malignancies
    • Abstract Number: P250
    • Date and Time: Friday June 13, 2014, 5:45pm – 7:00pm CEST
    • Poster Display: NW- Level 0
    • Lead Author: Howard A. Burris, MD

In addition to the above, at the 50th Annual Meeting of American Society of Clinical Oncology (ASCO), which is being held next week from May 30 – June 3, 2014 in Chicago, Illinois, the Company will present safety, efficacy, and pharmacokinetic data from TG Therapeutics' ongoing Phase 1 studies of TG-1101 and TGR-1202 as single agents in patients with advanced hematologic malignancies.

Finally, a clinical update on the combination study of TG-1101 and TGR-1202 will be presented at the 2014 Pan Pacific Lymphoma Conference to be held in Hawaii on July 21 – 25, 2014.


TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.


CONTACT: Jenna Bosco Director - Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email:

Source:TG Therapeutics, Inc.